Effect of combined treatment of patients with type 2 diabetes and coronary heart disease on lipid metabolism and anthropometric data

Abstract

The article presents the results of the investigation of the dynamics of lipid metabolism and anthropometric data in patients with type 2 diabetes (T2DM) and  coronary heart disease (CHD) treated with metformin (MF) and pioglitazone (PG). We have treated 95 patients with coronary heart disease and type 2 diabetes. All  patients were randomized into 2 groups: control group (37 patients) which received metformin and sulfonylureas and observational group (58 patients), which  received pioglitazone in addition to metformin therapy. The proposed course of therapy lasted 6 months. Use of the proposed combined treatment of patients with  type 2 diabetes and CHD  resulted in a statistically significant improvement in lipid metabolism, patients’ body weight and visceral obesity. Also, it was well tolerated and improved quality of life.